Sight Sciences, Inc. (SGHT) Investment Analysis
1. Executive Summary
Sight Sciences, Inc. (SGHT) is an ophthalmic medical technology company focused on developing and commercializing surgical and non-surgical interventional technologies to address highly prevalent and underserved eye diseases, specifically open-angle glaucoma and dry eye disease (DED).[1, 2] The firm generates revenue by selling medical devices and single-use consumables across two primary segments: Interventional Glaucoma and Interventional Dry Eye.[3, 4] Its target customer base consists of ophthalmic surgeons, ambulatory surgery centers (ASCs), hospital outpatient departments (HOPDs), and office-based eye care professionals (ECPs).[2, 5] The vast majority of its revenues are currently derived from the United States.[5, 6]
The core of the Sight Sciences product suite is built on two primary therapeutic platforms [2, 7]:
- OMNI Surgical System: An implant-free, single-use, therapeutic device cleared by the FDA for the reduction of intraocular pressure (IOP) in adult open-angle glaucoma patients.[2]
- TearCare System: An open-eye, wearable, localized heat-therapy system indicated for adult patients with evaporative dry eye disease caused by meibomian gland dysfunction (MGD).[1, 2]
Sight Sciences also commercializes the SION Surgical Instrument, an implant-free, manual goniotomy device used during surgical glaucoma procedures.[6, 8]
Historically, open-angle glaucoma and evaporative dry eye have been treated via daily prescription eye drops, which are often limited by poor patient adherence, local toxicity, and progressive disease pathology.[2, 5, 9] Eyecare professionals choose Sight Sciences' technologies over conventional alternatives due to their ability to target the root physiological causes of these diseases in a minimally invasive, procedure-based manner.[2, 7] OMNI provides a distinct structural advantage by accessing all $360^\circ$ of Schlemm's canal and addressing all three primary sources of outflow resistance through a single clear corneal microincision.[2] TearCare offers a highly customizable, blink-assisted, open-eye design that allows patients to blink naturally during localized thermal therapy, enabling superior meibum softening and subsequent manual gland evacuation.[2, 10, 11]
2. Business Drivers and Strategic Overview
The OMNI Surgical System is engineered as a handheld, single-use device that enables surgeons to perform two distinct, well-established surgical procedures—canaloplasty (microcatheterization and viscodilated expansion of Schlemm’s canal) and trabeculotomy (unroofing of the trabecular meshwork)—sequentially.[2, 6] This dual action addresses the conventional aqueous outflow pathway without leaving a permanent metallic or synthetic implant in the eye.[2]
The TearCare System comprises flexible, adhesive SmartLids designed to conform to the anatomy of the upper and lower eyelids.[2, 12] The SmartLids are connected to a reusable SmartHub, which delivers controlled thermal energy at approximately $45^\circ\text{C}$ to the meibomian glands for 15 minutes.[11, 12] Once the heat has softened the hardened lipid obstructions (meibum), the treating clinician uses a specialized clearance instrument to manually express the glands.[2, 12, 13]
Moat Analysis
Sight Sciences' economic moat is structured around high switching costs, intellectual property, and a growing body of clinical evidence [5, 8, 14]:
- Switching Costs: Ophthalmic microsurgery requires high precision and specialized manual dexterity. Once a surgeon undergoes the extensive training curve to master the ab interno placement and deployment of the OMNI microcatheter, they are highly unlikely to shift to alternative modalities due to the operational risk and workflow disruption associated with re-training.[2, 6]
- Intellectual Property (IP): The firm maintains a robust patent portfolio protecting its circumferential microcatheterization and localized thermal therapy designs.[15] This IP was recently validated in a Delaware federal court, which upheld a jury verdict finding that Alcon Inc. willfully infringed Sight Sciences' patents via the sale of its Hydrus Microstent, resulting in a final damages judgment of $55.4 million and an ongoing 10% royalty on Alcon's Hydrus revenue.[4, 14, 16]
- Clinical Differentiation: Since 2018, there have been 34 peer-reviewed articles published supporting the efficacy of OMNI.[5] Real-world clinical registry evaluations (such as the AAO's IRIS Registry) have demonstrated sustained 36-month efficacy in reducing both IOP and dependency on hypotensive medications, creating a high barrier for unproven generic or late-market entrants.[5]
Addressable Market Opportunity
Sight Sciences estimates its total addressable market (TAM) in the United States to be approximately $16.0 billion [2, 6]:
| Segment |
Estimated TAM |
Penetration Dynamic |
| Surgical Glaucoma (OMNI) |
\$6.0 billion [2, 6] |
~\$1.0B in combination cataract procedures; ~\$5.0B in standalone interventions.[6] Underpenetrated, with historical manufacturers capturing less than one-third of the cataract combination market.[6] |
| Interventional Dry Eye (TearCare) |
\$10.0 billion [2, 6] |
Driven by the fact that evaporative DED from MGD accounts for approximately 86% of all DED cases, representing a massive untreated patient pool.[6] |
Competitive Landscape
The minimally invasive glaucoma surgery (MIGS) and dry eye spaces are highly competitive.[17, 18]
In Surgical Glaucoma, Sight Sciences competes primarily against major med-tech players including Glaukos Corporation (marketing the iStent inject and the newly launched iDose TR) [18, 19, 20] and Alcon (marketing the Hydrus Microstent).[15, 19] While Glaukos has experienced rapid growth with its iDose TR drug delivery platform, it faces legacy cataract-MIGS headwind restrictions.[18] Sight Sciences is successfully holding its ground; the Medicare Local Coverage Determinations (LCDs) implemented in late 2024 restricted the combination of multiple MIGS devices during cataract surgeries, which stabilized the market environment for OMNI as a foundational standalone and single-MIGS procedure.[13, 21, 22]
In the dry eye market, TearCare competes directly with Johnson & Johnson Vision’s LipiFlow Thermal Pulsation System and Alcon’s Systane iLux.[10, 11] LipiFlow is an automated system applying simultaneous heat and pressure, costing up to $900 per session.[10, 11] iLux is a handheld spot-treatment device.[10, 11] Sight Sciences is actively gaining ground in this market following a crucial reimbursement turning point in late 2025: the Medicare Administrative Contractors (MACs) Novitas Solutions and First Coast Service Options established jurisdiction-wide coverage and carrier-priced fee schedules for CPT code 0563T (TearCare) at approximately $1,142 per procedure.[9, 13] This covers 10.4 million Medicare lives and is driving immediate commercial acceleration over competitors.[9, 13]
3. Financial Performance and Valuation
Sight Sciences reported its financial results for the first quarter of fiscal year 2026 (ended March 31, 2026) on May 6, 2026.[3, 23]
- Revenue: Total revenue was $19.7 million, representing a 12.5% increase year-over-year compared to $17.5 million in Q1 2025.[3, 14, 17] This performance beat analyst consensus estimates of $18.47 million (or $18.55 million) by 6.2%.[3, 17, 23]
- Earnings Per Share (EPS): GAAP EPS was -$0.24, missing analyst consensus expectations of -$0.17 to -$0.19 by approximately $0.05 to $0.07 (representing a 41.18% negative variance).[3, 17, 23] The earnings miss was driven by a one-time $5.4 million success fee paid to legal counsel following the final Alcon patent litigation judgment.[4, 7, 14]
- Operating Expenses & Adjusted Profitability: Total GAAP operating expenses rose slightly by 2% to $29.4 million.[4, 7] However, excluding the $5.4 million litigation success fee, adjusted operating expenses declined by 14% to $21.2 million, highlighting the success of the firm's cost management and restructuring program initiated in late 2025.[7, 24] GAAP net loss narrowed to $13.0 million, compared to a net loss of $14.2 million in Q1 2025.[3, 14, 17]
- Cash and Debt Balance: Cash and cash equivalents stood at $85.0 million as of March 31, 2026.[3, 14] Cash usage during the first quarter was reduced to $7.0 million, a 40% improvement from the $11.6 million cash outflow in the prior-year period.[4, 7] Outstanding term loan debt (Hercules Capital facility) remained flat at $40.0 million.[3, 13, 14]
The quarterly performance was characterized by diverging trajectories across its two core segments [3, 4, 7]:
| Segment |
Revenue (Q1 2026) |
Year-over-Year Growth |
Gross Margin |
| Surgical Glaucoma |
\$18.34 million [4] |
+7% [7] |
87.0% [7] |
| Interventional Dry Eye |
\$1.35 million [4] |
+244% [3] |
72.0% [7] |
| Total Portfolio |
\$19.70 million [3] |
+12.5% [14] |
86.2% [3] |
- Surgical Glaucoma: Growth was supported by a 6% increase in ordering accounts and higher average selling prices, though partially offset by lower per-account utilization.[7]
- Interventional Dry Eye: Revenue acceleration was driven by the newly established MAC fee schedules in the First Coast and Novitas regions, where active accounts rose to 96, SmartLids unit sales more than doubled to 1,534, and utilization per active account expanded from 9 to 16 procedures sequentially.[4, 7, 17]
On the back of the Q1 2026 results, Sight Sciences updated its full-year 2026 guidance [3, 4]:
- Revenue Guidance: Raised to a range of $83.0 million to $89.0 million (representing 7% to 15% annual growth), up from the prior guidance of $82.0 million to $88.0 million.[3, 4]
- Segment Composition: Anticipates $77.0 million to $81.0 million in Interventional Glaucoma revenue (2% to 7% growth) and $6.0 million to $8.0 million in Interventional Dry Eye revenue (representing significant growth compared to the $1.6 million generated in FY2025).[4, 25]
- Adjusted Operating Expense Guidance: Reaffirmed at $93.0 million to $96.0 million, reflecting continued disciplined commercial investment to drive standalone OMNI and reimbursed TearCare expansion.[4, 13]
Management emphasized the "intersection of intervention," a strategy to cross-sell TearCare into the firm's existing glaucoma customer base, where customer overlap is highly prevalent.[7, 17, 26] Leadership reiterated its commitment to achieving cash flow breakeven without raising additional equity capital, supported by its current $85.0 million cash cushion.[7, 13]
The immediate post-earnings market reaction was relatively stable, with the stock declining a minor 0.69% to close at $4.33 on May 6, 2026.[17, 27] This stability suggests that investors had already priced in the near-term profitability impact of the $5.4 million legal success fee, focusing instead on the underlying 13% top-line growth and the major $55.4 million patent victory.[3, 14, 17] By July 2026, the stock had recovered to trade at approximately $5.52, aligning with constructive intermediate price consolidation.[28]
Sight Sciences currently commands an enterprise value (EV) of approximately $253.33 million on a market capitalization of $296.53 million, benefiting from a net cash position ($84.96 million cash minus $41.76 million total debt).[29]
| Valuation Metric |
Value |
| Current Share Price (July 2026) |
\$5.52 [28] |
| Shares Outstanding |
54.03 million [4] |
| Price-to-Sales (TTM) |
3.7x [30] |
| Enterprise Value / Revenue (TTM) |
3.2x [30] |
| Interest Coverage Ratio (LTM) |
-1.57x [31] |
| 5-Year Sales CAGR (2020–2025) |
22.8% [25, 32] |
Over the five-year period from 2020 ($27.64 million) to 2025 ($77.36 million), revenues grew at a CAGR of 22.8%.[25, 32] While growth stalled in 2024 and 2025 due to transient reimbursement headwinds in the combination cataract MIGS space, the structural growth model is inflecting upward as the company moves into high-margin, office-based dry eye procedures.[13, 32, 33]
The Price-to-Sales multiple of 3.7x represents a significant discount to its peer average of 8.5x, reflecting the market’s caution regarding its structural unprofitability.[30] However, connecting valuation to its gross margin of 86.2%, any sustainable acceleration in top-line growth could result in significant operating leverage and multiple expansion.[3, 30]
4. Risk Assessment and Macroeconomic Considerations
Execution Risks
The primary execution risk centers on the commercial scaling of the TearCare system.[24] While current traction in the Novitas and First Coast MAC regions is robust, these regions represent only a fraction of the total U.S. market.[9, 13] If Sight Sciences fails to secure jurisdiction-wide pricing and coverage from the remaining MACs, the Interventional Dry Eye segment could experience a growth ceiling, failing to justify the ongoing commercial expansion investments.[4, 24]
- Early Warning Sign: A sequential flattening of SmartLids consumable volume or a stagnation in active dry eye accounts below 150 in the next two quarters.[4, 7]
- Thesis Damage: Failure of a major MAC (such as Noridian or CGS) to establish favorable coverage, forcing the company to rely on out-of-pocket cash patients.[9, 24]
Competitive Risks
The glaucoma sector is characterized by intense product innovation. The rapid adoption of Glaukos' iDose TR and Alcon's automated contactless Voyager SLT laser could diminish Standalone OMNI utilization.[18, 20] Additionally, while the Delaware District Court awarded Sight Sciences $55.4 million in past damages and a 10% royalty on Alcon's Hydrus revenue, this judgment remains subject to appeal.[4, 16] Alcon has initiated ex parte reexaminations at the USPTO seeking to invalidate the asserted patents.[14, 16, 34]
- Early Warning Sign: A decline in Surgical Glaucoma revenue below the guided $77.0 million floor or a negative preliminary ruling by the Patent Trial and Appeal Board (PTAB).[4, 14]
- Thesis Damage: Complete invalidation of the asserted patent claims by the USPTO, which would erase the $55.4 million damages award, cancel the 10% ongoing royalty stream, and impair the structural IP barrier protecting the OMNI technology.[14, 16, 34]
Balance Sheet Risks
Sight Sciences carries $40.0 million in long-term debt under a Hercules Capital facility.[3, 14] This facility carries a floating interest rate based on the greater of 10.35% or the WSJ prime rate plus 2.35%.[35, 36] This structures a vulnerability to high interest expense in a sustained "higher-for-longer" macroeconomic rate environment.[35, 36] While cash reserves of $85.0 million provide sufficient runway, an escalation in cash burn would force dilutive equity financing before reaching profitability.[3, 7]
- Early Warning Sign: Cash usage expanding back above $10.0 million per quarter or interest expenses rising significantly.[7, 14]
- Thesis Damage: Cash runway depleting to under 12 months without narrowing operating losses, forcing a highly dilutive capital raise at depressed valuations.
5. 5-Year Scenario Analysis
The following projections evaluate potential share price outcomes for Sight Sciences over a five-year horizon (ending FY2031). Operating assumptions are built upon current outstanding shares of 54.03 million and a current share price of $5.52.[4, 28]
Base Case Scenario (55% Probability)
The Base Case assumes Sight Sciences returns to steady double-digit revenue growth driven by expanding TearCare reimbursement to at least two additional MAC regions.[9, 13] Standalone OMNI adoption grows moderately as clinical registry data reinforces its 36-month efficacy.[5]
- Financial Assumptions: Five-year revenue CAGR of 12% on the 2026 midpoint revenue baseline of $86.0 million [4], resulting in Year 5 (FY2031) revenue of $151.56 million. The company reaches cash flow breakeven by FY2029 [7, 13], achieving a net profit margin of 15% by FY2031, which implies net income of $22.73 million.
- Valuation & Dilution: Outstanding shares expand to 60.0 million due to standard option and performance RSU vesting.[14] With a stabilized profit profile and high gross margins, the firm commands a 4.0x Price-to-Sales (P/S) multiple.
- Bridge to Price Target:
$\text{Future Market Cap} = \$151.56\text{ million (Revenue)} \times 4.0\text{x Multiple} = \$606.24\text{ million}$ $\text{Implied Future Share Price} = \frac{\$606.24\text{ million}}{60.0\text{ million shares}} = \$10.10$
High Case Scenario (25% Probability)
The High Case assumes a highly favorable resolution of the Alcon patent litigation.[4] Sight Sciences successfully collects the $55.4 million judgment and receives an estimated $25.0 million in accumulated 10% royalties on Hydrus through late 2028.[16, 37] TearCare secures universal MAC coverage, establishing it as the clear market leader in DED thermal pulsation.[9, 13]
- Financial Assumptions: Five-year revenue CAGR of 18%, driven by massive interventional dry eye adoption, leading to FY2031 revenue of $196.75 million. Strong operating leverage expands Year 5 net margins to 20%, resulting in net income of $39.35 million.
- Valuation & Dilution: Dilution is mitigated via cash-flow-driven share buybacks, keeping outstanding shares at 58.0 million.[7, 13] The legal cash windfall of $80.4 million is held on the balance sheet.[4] The firm commands an exit P/S multiple of 5.5x.
- Bridge to Price Target:
$\text{Operating Value} = \$196.75\text{ million (Revenue)} \times 5.5\text{x Multiple} = \$1,082.13\text{ million}$ $\text{Total Market Cap} = \$1,082.13\text{ million} + \$80.4\text{ million (Litigation Cash)} = \$1,162.53\text{ million}$ $\text{Implied Future Share Price} = \frac{\$1,162.53\text{ million}}{58.0\text{ million shares}} = \$20.04$
Low Case Scenario (20% Probability)
The Low Case assumes Alcon wins its appeal, overturning the patent judgment.[4, 14] Concurrently, USPTO reexaminations invalidate key OMNI patents.[14, 34] Competitive pressure from Glaukos' iDose TR severely erodes OMNI’s market share [18], while TearCare fails to obtain coverage beyond the original two MAC regions, forcing the company to scale back its dry eye operations.[24]
- Financial Assumptions: Revenue growth stagnates at a 2% CAGR, resulting in FY2031 revenue of $94.95 million. The company struggles to control expenses and remains barely at breakeven with a 1% net margin ($0.95 million net income).
- Valuation & Dilution: The firm is forced to execute capital raises, increasing outstanding shares to 65.0 million. The exit multiple contracts to a distressed 1.5x P/S.
- Bridge to Price Target:
$\text{Future Market Cap} = \$94.95\text{ million (Revenue)} \times 1.5\text{x Multiple} = \$142.43\text{ million}$ $\text{Implied Future Share Price} = \frac{\$142.43\text{ million}}{65.0\text{ million shares}} = \$2.19$
Expected Value Price Target (Probability-Weighted)
The mathematical expected share price of Sight Sciences is calculated as:
$\text{Expected Value} = (0.25 \times \$20.04) + (0.55 \times \$10.10) + (0.20 \times \$2.19) = \$5.01 + \$5.56 + \$0.44 = \$11.01$
This yields an expected value price target of $11.01, representing an implied 99.5% 5-year total return and a 14.8% annualized return from the current share price of $5.52.[28]
| Scenario |
Revenue in Year 5 |
Margin / Earnings Assumption |
Valuation Multiple |
Current Share Price (USD) |
Implied Future Share Price (USD) |
5-Year Total Return |
Annualized Return |
Probability |
| High Case |
\$196.75M |
20.0% Net Margin / \$39.35M Net Income |
5.5x P/S (plus \$80.4M litigation cash) [4] |
\$5.52 [28] |
\$20.04 |
+263.0% |
+29.4% |
25% |
| Base Case |
\$151.56M |
15.0% Net Margin / \$22.73M Net Income |
4.0x P/S |
\$5.52 [28] |
\$10.10 |
+83.0% |
+12.8% |
55% |
| Low Case |
\$94.95M |
1.0% Net Margin / \$0.95M Net Income |
1.5x P/S |
\$5.52 [28] |
\$2.19 |
-60.3% |
-16.9% |
20% |
| Expected Value |
\$142.06M |
13.0% Net Margin / \$18.47M Net income |
3.8x P/S |
\$5.52 [28] |
\$11.01 |
+99.5% |
+14.8% |
100% |
ASYMMETRIC GROWTH POTENTIAL
6. Qualitative Scorecard
To evaluate the qualitative dimensions of Sight Sciences, the firm has been scored across ten key operational and financial metrics on a scale of 1 to 10:
| Metric |
Score |
Key Driver |
| Management Alignment |
7/10 |
Paul and David Badawi retain significant equity stakes, with the CEO holding over 5.54M shares.[29] Chairman Staffan Encrantz bought 14,100 shares at $4.88 in June 2026.[27, 29] However, open-market executive sales to cover tax liabilities create minor overhangs.[38, 39] |
| Revenue Quality |
9/10 |
Outstanding revenue quality with an 86.2% gross margin.[3] Built on high-margin single-use surgical packs and high-frequency disposable SmartLids consumables.[2, 7] |
| Market Position |
6/10 |
OMNI has a validated position in ab interno MIGS with strong 36-month real-world clinical data.[5] However, it faces intense pressure from Glaukos (iDose TR) [18] and Alcon.[15, 19] |
| Growth Outlook |
8/10 |
Positive near-term inflection with raised FY2026 revenue guidance.[4] Expanding TearCare reimbursement and the upcoming launch of OMNI Ultra provide solid catalysts.[4, 7] |
| Financial Health |
7/10 |
High liquidity with $85.0M in cash against $40.0M in debt [3, 14] and an impressive current ratio of 9.6.[26] Q1 2026 cash burn was managed down to $7.0M.[4, 7] |
| Business Viability |
8/10 |
High durability as the underlying pathologies of open-angle glaucoma and dry eye are permanent, chronic eye conditions.[1, 2] |
| Capital Allocation |
6/10 |
Management has pivoted toward expense control, reducing non-legal OPEX by 14%.[7] However, historical spending has resulted in a large accumulated deficit of $397.7M.[14, 33] |
| Analyst Sentiment |
8/10 |
Solid sell-side consensus, with the majority of covering analysts recommending a "Buy".[40, 41] Average 12-month targets of $8.54 - $8.86 suggest clear fundamental undervaluation.[40, 41] |
| Profitability |
3/10 |
Current unprofitability remains a primary drag, with a net loss of $13.0M in the latest quarter and a negative interest coverage ratio of -1.57x.[3, 31] |
| Track Record |
4/10 |
Poor historical performance, with the stock trading down severely from its $24.00 IPO price [2] and experiencing revenue stagnation over 2024–2025.[32] |
| Blended Score |
6.6/10 |
Balanced operational improvements offset by historical execution volatility. |
STABILIZING TURNAROUND PROFILE
7. Conclusion and Investment Thesis
Sight Sciences is navigating a fundamental operational transition.[24] The investment thesis is centered on the asymmetric potential of its high-margin consumable model [7, 17], supported by three distinct near-term catalysts:
- Dry Eye Commercial Inflection: The carrier-priced Medicare reimbursement of TearCare at ~$1,142 per procedure is a significant development.[9, 13] By transforming dry eye from an out-of-pocket luxury to a reimbursed clinical procedure, Sight Sciences is demonstrating early sequential compounding in active accounts and volume.[7, 13]
- Surgical Glaucoma Stabilization: Despite severe sector headwinds following late-2024 LCD restrictions, the OMNI Surgical System has established itself as a resilient standalone option.[13] The impending regulatory approval and launch of OMNI Ultra by late 2026 presents a solid product pipeline catalyst.[7]
- Litigation Optionality: The $55.4 million final judgment against Alcon represents an underappreciated asset.[4] While subject to appeal [4], a successful resolution would infuse Sight Sciences with cash equal to nearly 27% of its current enterprise value, accelerating its path to profitability without equity dilution.[7, 29]
Although structural unprofitability [3], floating debt exposure [35], and USPTO patent reexaminations [14] present near-term risks, the current valuation of 3.7x Price-to-Sales suggests the market is discounting its 86.2% gross margins and accelerating growth profile.[3, 30]
DISCOUNTED OPTIONALITY PLAY
8. Technical Analysis, Price Action and Short-Term Outlook
Technically, Sight Sciences has demonstrated constructive relative strength, closing at $5.52, well within its 52-week range of $3.11 to $9.24.[28] The stock crossed above its 200-day simple moving average on June 18, 2026, following a strong 11.5% weekly surge driven by the preservation of the Delaware patent verdict.[34, 42] Currently, the price is consolidating in a tight trading band between near-term support at $4.79 and horizontal resistance at $5.29 [43], indicating a healthy accumulation phase ahead of its next quarterly earnings announcement estimated for August 6, 2026.[23, 28]
BULLISH PATTERN CONSOLIDATION
- Ophthalmic Devices Market Report 2026 - Research and Markets, https://www.researchandmarkets.com/reports/5781104/ophthalmic-devices-market-report
- 424B4 - SEC.gov, https://www.sec.gov/Archives/edgar/data/1531177/000119312521216560/d90195d424b4.htm
- Sight Sciences (SGHT) Stock News & Updates | StockTitan, https://www.stocktitan.net/news/SGHT/
- Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance - United States, https://www.sightsciences.com/us/sight-sciences-reports-first-quarter-2026-financial-results-and-raises-full-year-2026-revenue-guidance/
- Sight Sciences (SGHT) outlines interventional glaucoma and dry eye growth plan, https://www.stocktitan.net/sec-filings/SGHT/10-k-sight-sciences-inc-files-annual-report-c09a3b2a020c.html
- Sight Sciences: A Visionary in the Field of Ophthalmology - Avise Analytics, https://www.aviseanalytics.com/sight-sciences-a-visionary-in-the-field-of-ophthalmology/
- Sight Sciences (SGHT) Q1 2026 Earnings Transcript | The Motley Fool, https://www.fool.com/earnings/call-transcripts/2026/05/06/sight-sciences-sght-q1-2026-earnings-transcript/
- 10-K - SEC.gov, https://www.sec.gov/Archives/edgar/data/1531177/000119312526091558/sght-20251231.htm
- Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript | Seeking Alpha, https://seekingalpha.com/article/4839943-sight-sciences-inc-sght-q3-2025-earnings-call-transcript
- 11 Devices for Treating Dry Eyes - American Academy of Ophthalmology, https://www.aao.org/eye-health/tips-prevention/how-to-treat-dry-eye-devices
- A Comparative Guide to Thermal Pulsation Devices for Dry Eye, https://eyesoneyecare.com/resources/a-comparative-guide-to-thermal-pulsation-devices-for-dry-eye/
- A Comparison of TearCare and Lipiflow Systems in Reducing Dry Eye Disease Symptoms Associated with Meibomian Gland Disease - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC9440678/
- Sight Sciences (SGHT) Q4 2025 Earnings Transcript | The Motley Fool, https://www.fool.com/earnings/call-transcripts/2026/03/04/sight-sciences-sght-q4-2025-earnings-transcript/
- Sight Sciences (NASDAQ: SGHT) grows Q1 2026 sales and wins $55.4M judgment, https://www.stocktitan.net/sec-filings/SGHT/10-q-sight-sciences-inc-quarterly-earnings-report-087045a68cf4.html
- Sight Sciences Secures $34M Verdict and Ongoing Royalties From Alcon in Patent Dispute, https://www.mddionline.com/medical-device-markets/sight-sciences-secures-34m-verdict-and-ongoing-royalties-from-alcon-in-patent-dispute
- 8-K - SEC.gov, https://www.sec.gov/Archives/edgar/data/1531177/000119312526171887/sght-20260422.htm
- Earnings call transcript: Sight Sciences Q1 2026 revenue up, EPS misses - Investing.com, https://www.investing.com/news/transcripts/earnings-call-transcript-sight-sciences-q1-2026-revenue-up-eps-misses-93CH-4665744
- Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks - TradingView, https://www.tradingview.com/news/zacks:b6b074faf094b:0-glaukos-ramps-up-idose-tr-battles-legacy-and-reimbursement-risks/
- Micro Invasive Glaucoma Surgery (MIGS) Devices Market Size, Trends, Growth Report 2033, https://www.databridgemarketresearch.com/reports/global-micro-invasive-glaucoma-surgery-migs-devices-market
- GLAUCOMA THERAPIES: PAST, PRESENT AND FUTURE - Saber UCV, https://saber.ucv.ve/ojs/index.php/rov/article/view/32894/144814497770
- Response to Comments: Micro-Invasive Glaucoma Surgery (MIGS) (A59912) - CMS, https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=59912&ver=3
- OMNI® Surgical System SION® Surgical Instrument - Sight Sciences, https://www.sightsciences.com/us/wp-content/uploads/sites/4/2025/04/2025-OMNI-and-SION-Reimbursment-Guide-FINAL.pdf
- Sight Sciences (SGHT) Earnings Date and Reports 2026 - MarketBeat, https://www.marketbeat.com/stocks/NASDAQ/SGHT/earnings/
- Sight Sciences outlines $82M–$88M 2026 revenue target while expanding interventional dry eye strategy - Seeking Alpha, https://seekingalpha.com/news/4561046-sight-sciences-outlines-82m-88m-2026-revenue-target-while-expanding-interventional-dry-eye
- Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance, https://investors.sightsciences.com/news-releases/news-release-details/sight-sciences-reports-fourth-quarter-and-full-year-2025/
- Earnings call transcript: Sight Sciences beats Q4 2025 forecasts, stock rises - Investing.com, https://www.investing.com/news/transcripts/earnings-call-transcript-sight-sciences-beats-q4-2025-forecasts-stock-rises-93CH-4542481
- Sight Sciences Inc Stock Price Today | NASDAQ: SGHT Live - Investing.com, https://www.investing.com/equities/sight-sciences
- Sight Sciences: SGHT Stock Price Quote & News - Robinhood, https://robinhood.com/us/en/stocks/SGHT/
- Sight Sciences, Inc. (SGHT) Stock Price, Quote, News & Analysis | Seeking Alpha, https://seekingalpha.com/symbol/SGHT
- Sight Sciences (NasdaqGS:SGHT) Stock Valuation, Peer Comparison & Price Targets, https://simplywall.st/stocks/us/healthcare/nasdaq-sght/sight-sciences/valuation
- Sight Sciences (SGHT) Interest Coverage Ratio (2020 - 2025) - Business Quant, https://businessquant.com/metrics/sght/interest-coverage-ratio-annual
- Sight Sciences (SGHT) - Revenue - Companies Market Cap, https://companiesmarketcap.com/sight-sciences/revenue/
- Sight Sciences Reports Preliminary Fourth Quarter 2025 Revenue Growth, Provides 2026 Outlook - Vision Monday, https://www.visionmonday.com/business/article/sight-sciences-reports-preliminary-fourth-quarter-2025-revenue-growth-provides-2026-outlook/
- Sight Sciences awarded $55.4 million in patent case against Alcon - Investing.com, https://www.investing.com/news/sec-filings/sight-sciences-awarded-554-million-in-patent-case-against-alcon-93CH-4632398
- 8-K - SEC.gov, https://www.sec.gov/Archives/edgar/data/1531177/000119312524012979/d715146d8k.htm
- Sight Sciences secures $5 million in additional loan funding - Investing.com Nigeria, https://ng.investing.com/news/sec-filings/sight-sciences-secures-5-million-in-additional-loan-funding-93CH-1671424
- Sight Sciences Secures Order on Post-Trial Motions - Cooley, https://www.cooley.com/news/coverage/2026/2026-04-23-sight-sciences-secures-order-on-post-trial-motions
- Form 4 Sight Sciences Inc For: 6 July - Investing.com UK, https://uk.investing.com/news/stock-market-news/form-4-sight-sciences-inc-for-6-july-93CH-4758634
- Form 4 Sight Sciences Inc For: 6 July - Investing.com Canada, https://ca.investing.com/news/stock-market-news/form-4-sight-sciences-inc-for-6-july-93CH-4722003
- Sight Sciences (SGHT) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026, https://public.com/stocks/sght/forecast-price-target
- Sight Sciences (SGHT) Stock Forecast & Price Target - Investing.com, https://www.investing.com/equities/sight-sciences-consensus-estimates
- Sight Sciences (SGHT) Free Cash Flow (TTM) - Zacks.com, https://www.zacks.com/stock/chart/SGHT/fundamental/free-cash-flow-ttm
- Sight Sciences (SGHT) Climbs +2.86% — Resistance at $5.29 in Focus 2026-05-14, https://bvwd.ca.gov/expert-time/Sight-Sciences-SGHT-Climbs-286-Resistance-at-529-in-Focus-20260514-15-2401